市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | ADC Therapeutics SA | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | -1.5 |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.70 |
|
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 21.58% |
| 机构持股比例 | 66.89% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tcg Crossover Management, Llc | 31 Mar 2026 | 11,390,175 |
| Prosight Management, Lp | 31 Mar 2026 | 8,300,000 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| AZELBY ROBERT | - | 3.08 | -12,600 | -38,808 |
| BIZZARI JEAN-PIERRE | - | 3.08 | -12,600 | -38,808 |
| COUGHLIN TIMOTHY | - | 3.08 | -12,600 | -38,808 |
| HUG PETER | - | 3.08 | -2,156 | -6,640 |
| MONGES VIVIANE | - | 3.08 | -2,596 | -7,996 |
| SANDOR VICTOR | - | 3.08 | -12,600 | -38,808 |
| SQUARER RON | - | 3.08 | -15,196 | -46,804 |
| 累积净数量 | -70,348 | |||
| 累积净值 ($) | -216,672 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 3.08 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| COUGHLIN TIMOTHY | 董事 | 03 Jun 2026 | 处理 (-) | 12,600 | 3.08 | 38,808 |
| BIZZARI JEAN-PIERRE | 董事 | 03 Jun 2026 | 处理 (-) | 12,600 | 3.08 | 38,808 |
| HUG PETER | 董事 | 03 Jun 2026 | 处理 (-) | 2,156 | 3.08 | 6,640 |
| MONGES VIVIANE | 董事 | 03 Jun 2026 | 处理 (-) | 2,596 | 3.08 | 7,996 |
| SANDOR VICTOR | 董事 | 03 Jun 2026 | 处理 (-) | 12,600 | 3.08 | 38,808 |
| SQUARER RON | 董事 | 03 Jun 2026 | 处理 (-) | 15,196 | 3.08 | 46,804 |
| AZELBY ROBERT | 董事 | 03 Jun 2026 | 处理 (-) | 12,600 | 3.08 | 38,808 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合